Benjamin Dryden on Government View of Merger Remedies – ‘No secret they are skeptical’
22 April 2024
Foley & Lardner LLP partner Benjamin Dryden assessed the U.S. Department of Justice’s and Federal Trade Commission’s increasingly aggressive scrutiny on mergers in the Law360 article, “What We’ve Learned From Biden-Era Merger Remedies.”
“They’ve made no secret of the fact that they are skeptical of merger remedies,” commented Dryden, who is vice-chair of Foley’s Antitrust & Competition Practice.
He explained that companies have realized that while government agencies are unlikely to accept offered remedies to address competition concerns, “a court might.” As a result, companies are potentially more willing to fight enforcers in court.
(Subscription required)
People
Related News
17 May 2024
In the News
Foley’s IP Litigation Win Receives Shout Out in AmLaw Litigation Daily, Highlighted Across Legal Press
Foley & Lardner LLP’s recent delivery of summary judgment in a trademark and trade dress infringement case received coverage across legal press
14 May 2024
In the News
Thomas Ferrante on Interstate Health Policy Conflicts – ‘I’d definitely recommend paying attention’
Foley & Lardner LLP partner Thomas Ferrante offered insight on how a patchwork of shifting state legislation on health care issues are stretching constitutional limits
14 May 2024
In the News
Christopher Swift on China Biotech Crackdown – ‘There’ll be more self-initiated serious investigations into these kinds of transactions’
Foley & Lardner LLP partner Christopher Swift assessed the potential impact of the BIOSECURE Act – aimed at banning trade with major Chinese biotechnology firms